We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current TCRX market cap is 162.25M. The company's latest EPS is USD -1.6717 and P/E is -1.76.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 3.89M | 7.21M | 566k | 536k | 1.05M |
| Operating Income | -24.75M | -21.36M | -31.37M | -34.11M | -32.62M |
| Net Income | -23M | -19.61M | -30.14M | -31.66M | -29.89M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 1.09M | 10.14M | 13.54M | 21.05M |
| Operating Income | -14.21M | -26.23M | -48.64M | -66.64M | -93.46M |
| Net Income | -13.66M | -26.23M | -48.63M | -66.22M | -89.22M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 291.38M | 272.15M | 240.83M | 374.87M | 348.03M |
| Total Liabilities | 122.42M | 121.28M | 117.87M | 119.65M | 118.94M |
| Total Equity | 168.96M | 150.87M | 122.97M | 255.22M | 229.09M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 49.38M | 49.74M | 188.11M | 199.09M | 272.15M |
| Total Liabilities | 6.84M | 32.52M | 27.33M | 99.66M | 121.28M |
| Total Equity | -17.14M | -42.46M | 160.78M | 99.43M | 150.87M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -37.59M | -61.36M | -29.27M | -55.49M | -83.41M |
| Investing | -62.67M | -60.76M | 36.16M | 2.45M | -79.91M |
| Financing | 135.42M | 135.44M | 258k | 161.85M | 163.08M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -12.52M | -3.02M | -48.68M | -66.5M | -61.36M |
| Investing | -1.25M | -4.24M | -9.94M | -4.23M | -60.76M |
| Financing | 34.81M | 288k | 189.67M | 29.36M | 135.44M |
| Market Cap | 162.25M |
| Price to Earnings Ratio | -1.76 |
| Price to Sales Ratio | 7.48 |
| Price to Cash Ratio | 1.18 |
| Price to Book Ratio | 1.04 |
| Dividend Yield | - |
| Shares Outstanding | 53.37M |
| Average Volume (1 week) | 429.48k |
| Average Volume (1 Month) | 471.73k |
| 52 Week Change | -37.19% |
| 52 Week High | 9.69 |
| 52 Week Low | 2.60 |
| Spread (Intraday) | 0.2 (6.15%) |
| Company Name | TScan Therapeutics Inc |
| Address |
3500 s dupont hwy dover, delaware 19901 |
| Website | https://www.tscan.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
